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mutation group; the same results were observed in the vari-
ance analysis and rank sum test.
Conclusion The 19del mutation may be a more efficient 
clinical marker for predicting the response of patients with 
NSCLC to EGFR TKIs. Furthermore, patients with the 
19del mutation have both a longer PFS and OS. The 19del 
mutation is also the prognostic factor for patients with 
NSCLC.
Keywords NSCLC · EGFR · EGFR TKIs · Meta-analysis
Introduction
The small-molecule epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors (TKIs), such as erlo-
tinib and gefitinib, have been widely used in the treatment 
of advanced non-small cell lung cancer (NSCLC) (NCCN 
2014). With the IDEAL1 study proving the efficacy of gefi-
tinib for advanced NSCLC patients as a second-line treat-
ment in 2003 (Fukuoka et al. 2003), and the BR.21 study 
indicating the efficacy of erlotinib for advanced NSCLC 
patients with chemotherapy failure in 2005 (Tsao et al. 
2005), the development of EGFR TKIs was a milestone in 
NSCLC treatment.
Many studies have indicated that EGFR sensitive 
mutations are associated with a better efficacy of EGFR 
TKIs. Mokita’s analysis of seven clinical trials showed 
that patients with EGFR mutations responded better 
to EGFR TKIs, having a higher objective response rate 
(ORR) (79.3 %) and longer progression-free survival 
(PFS) (10.7 months) (Morita et al. 2009). A meta-analy-
sis of phase III clinical trails (Gao et al. 2012) (including 
IPASS/OPTIMAL/EURTAC.) also showed that EGFR 
TKIs in NSCLC patients with EGFR sensitive mutations 
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brought the ORR up as high as 66.6 %, with a median 
progression-free survival (mPFS) of 9.5 months and a 
median overall survival (mOS) of 30.5 months, as the 
first-line treatment. A recent pooled analysis (Paz-Ares 
et al. 2010) of 54 studies demonstrated that EGFR muta-
tions predict response to EGFR TKIs, with erlotinib and 
gefitinib treatment showing significantly higher mPFS 
times of 13.2 and 9.8 months, respectively, when com-
pared with only 5.9 months for chemotherapy treatment 
alone.
EGFR mutations occur almost exclusively within 
exons 18–21 of the gene, which encodes the amino lobe 
and part of the carboxy lobe of the receptor. Nearly 85 % 
of lung-cancer-specific EGFR mutations comprise a leu-
cine-to-arginine substitution at position 858 (21L858R) 
and a deletion mutation in exon 19 that affects the con-
served sequence LREA (19del) (Rosell et al. 2009). Is 
there any difference in response to EGFR TKIs between 
the two common types of patients with EGFR mutations? 
Several clinical studies suggested that patients with the 
exon 19 deletion had a better response rate, and a sig-
nificantly longer PFS and OS than patients with L858R 
(Mitsudomi et al. 2010; Fukuoka et al. 2011). However, 
several other studies indicated that the difference in 
EGFR TKI efficacy between the two subtypes of EGFR 
mutations is not statistically significant (Cappuzzo et al. 
2007).
We performed this meta-analysis, to compare the differ-
ence in EGFR TKI efficacy and determine the prognosis of 
advanced NSCLC patients with the two common subtypes 
of EGFR mutations (exon 19del and exon L858R), aiming 
to more accurately predict the response to EGFR TKIs and 




We performed a computerized search of Pubmed, Embase, 
and the Chinese National Knowledge Infrastructure 
(CNKI) database, we also manually searched the con-
ference proceedings of the American Society of Clini-
cal Oncology (ASCO), the European Society of Medical 
Oncology (ESMO) and the International Association for 
the Study of Lung Cancer from the year of 2000–2013 for 
relevant clinical trials. Reference lists from studies were 
also hand searched for this review. The following keywords 
were used: “NSCLC” or “non-small cell lung cancer” and 
“gefitinib or erlotinib” and “response.” There was no lan-
guage restriction.
Inclusion criteria
1. All prospective and retrospective studies were eligible 
for the study pool, only the most recent publication 
results from the same studies were included.
2. The patients who had a diagnosis of advanced NSCLC 
with stage III–IV and the patients harboring activating 
EGFR mutations (either exon 19 deletion or L858R in 
exon 21).
3. All patients received EGFR TKIs (gefitinib or erlo-
tinib) for monotherapy, first line or otherwise.
4. All the included patients were evaluated by their treat-
ment response, PFS and OS. Response Evaluation Cri-
teria on Solid Tumors (RECIST) criteria were used to 
define response, with “complete response” or “partial 
response” classified as “response,” and “stable” with 
no change, or “progressive”.
Exclusion criteria
1. Review, in vitro and animal experiments.
2. The objects of studies were not NSCLC patients.
3. The study of EFGR mutation in peripheral blood.
4. EGFR TKIs were used as maintenance or adjuvant 
therapy, or as sequential treatment with chemotherapy.
Quality assessment and data extraction
The randomized controlled studies were assessed in strict 
accordance with the Jadad scale (Jadad et al. 1996), and 
the other studies were assessed in terms of the Newcastle-
Ottawa Scale (NOS) (Wells et al. 2012; Stang 2010). To 
avoid evaluation deviation, two reviewers performed the 
assessment independently and discussed in order to reach 
an accordance when the information was unsatisfactory.
The following data were collected from each study: (1) 
general information: first author’s surname, publication 
time, source of the trial and the research type. (2) Features 
of the literature: clinical stage (AJCC staging), total num-
bers of the EGFR mutation types. (3) Evaluation indexes: 
ORR, PFS or TTP, and OS (Parmar et al. 1998).
Data analysis and statistical methods
The meta-analysis of risk ratios (RRs) for the objective 
responses to treatment and the meta-analysis of mean dif-
ferences (MDs) for PFS and OS were calculated using 
Review Manager (RevMan), version 5.2 (The Nordic 
Cochrane Centre, Copenhagen, Denmark) (The Cochrane 
Collaboration 2008).
A statistical test with a P value <0.05 was considered 
significant. RR > 1 reflects a better overall response rate 
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in the exon 19del arm, MD > 1 reflects fewer deaths or 
progression in the exon 19del arm and vice versa. In each 
meta-analysis, Cochran’s Q statistic and I2 statistics were 
calculated first in order to assess the heterogeneity among 
the proportions of the included trials. In case the P value 
was found to be <0.05, the assumption of homogeneity was 
deemed invalid and a random effects model was reported. 
Otherwise, a fixed effects model was reported. All P values 
were two sided. All CIs had a two-sided probability cover-
age of 95 %. If the study provided medians and interquar-
tile ranges instead of means and SDs, we inputed the means 
and SDs as described by Hozo et al. (2005). When the liter-
ature failed to provide the standard deviation, we estimated 
it with the maximum and minimum values of similar stud-
ies from the included literature.
At the same time, we performed variance analyses for 
the progression-free survival of both exon 19del and exon 
21L858R arms and used Mann–Whitney U test for the 
overall survival of both exon 19del and exon 21L858R 
arms, with a P value <0.05 considered to be significant. 




As shown in the NSCLC flow chart (Fig. 1), our initial 
search yielded 950 potentially relevant published arti-
cles. A review of the titles and abstracts of these articles 
resulted in 145 promising articles. These remaining 145 
articles were selected for analysis and evaluated in greater 
detail by reviewing the full articles. After exclusion of the 
studies that did not meet the inclusion criteria, 22 studies 
with 1,082 patients were included in the meta-analysis, 593 
patients with the exon 19del mutation and 489 patients with 
the exon 21L858R mutation. The characteristics of the eli-
gible studies are summarized in Table 1.
Response rate
Data for the ORR were available in 19 trials, with 12 pro-
spective trials and 7 retrospective trials, respectively. The 
I2 statistic in the fixed effects model did not demonstrate 
significant heterogeneity in the results (I2 37 %; P = 0.06); 
the fixed effects model was used to pool the risk ratio for 
the included studies.
Analysis of this data demonstrated that the ORR of 
the exon 19del group was 76.44 % (318/416), which was 
higher than the 60.66 % (202/333) found for the exon 
21L858R group,and the difference was statistically signifi-
cant. (RR = 1.23; 95 % CI 1.12–1.36; P < 0.0001) (Fig. 2).
Furthermore, subgroup analysis revealed that the ORR 
was significantly different between the two groups (pro-
spective trials: RR = 1.22, 95 % CI 1.10–1.36; retrospec-
tive trials: RR = 1.26, 95 % CI 1.03–1.53).
Progression-free survival
Data for the PFS were available in thirteen trials, with seven 
prospective trials and six retrospective trials, respectively. 
The standard deviation could be obtained in five trials; the 
range of the standard deviation values was 5.59–14.7 in 
prospective trials and 2.97–9.94 in retrospective trials.
We set the standard deviation to the minimum value of 
5.59 for the other four prospective trials, and the minimum 
value 2.97 was used for the other four retrospective trials. 
Because the I2 statistic in the fixed effects model demon-
strated statistically significant heterogeneity in the results 
(I2 92 %; P < 0.0001), a random effects model was used 
to pool the mean difference for the included studies. As 
Fig. 3 demonstrates, patients with exon 19del mutation 
had a statistically significant longer PFS than patients with 
exon 21L858R mutations (MD 3.55; 95 % CI 0.90–6.20; 
P = 0.009). As the subgroup analysis shows, in prospective 
trials, subgroup patients with the exon 19del mutation had 
a longer PFS than patients with the exon 21L858R muta-
tions, but the difference was not statistically significant 
(MD 2.68; 95 % CI −1.02 to 6.38; P = 0.16; I2 = 84 %; 
random effects model). However, patients with the exon 
19del mutation had a statistically significant longer PFS 
than patients with the exon 21L858R mutations in the ret-
rospective trials subgroup (MD 4.51; 95 % CI 0.46–8.56; 
P = 0.03; I2 = 96 %, random effects model).
Fig. 1  Electronic search flow chart
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Similarly, we repeated the analysis with the standard 
deviation set to the maximum value of 14.7 for the other 
four prospective trials, and the maximum value 9.94 for 
the other for retrospective trials. Because the I2 statistic in 
the fixed effects model demonstrated statistically signifi-
cant heterogeneity in the results (I2 42 %; P = 0.05), a ran-
dom effects model was used to pool the mean difference 
for the included studies. As Fig. 4 demonstrates, patients 
with the exon 19del mutation had a statistically significant 
longer PFS than patients with the exon 21L858R mutation 
(MD 2.57; 95 % CI 0.51–4.62; P = 0.01). As the subgroup 
analysis shows, in the prospective trials, subgroup patients 
with exon 19del mutation had a longer PFS than patients 
with exon 21L858R mutations, but the difference was not 
statistically significant (MD 1.42; 95 % CI −1.02 to 3.87; 
P = 0.25; I2 = 3 %, random effects model). However, 
patients with the exon 19del mutation had a statistically 
significant longer PFS than patients with the exon 21L858R 
mutations in the retrospective trials subgroup (MD 3.82, 
95 % CI 0.26–7.39; P = 0.04; I2 = 66 %, random effects 
model).
Overall survival (OS)
Data for the OS were available in three of the retrospec-
tive trials. The standard deviation for the OS could be 
obtained in Xu’s trial. But it was necessary to set the value 
for the other two trials. The I2 statistic in the fixed effects 
model did not demonstrate significant heterogeneity in the 
results (I2 0 %; P = 0.42), so the fixed effects model was 
used to pool the mean difference for the included stud-
ies. As shown in Fig. 5, patients with exon 19del mutation 
had a statistically significant longer OS than patients with 
exon 21L858R mutation (MD 10.52; 95 % CI: 5.10–15.93; 
P = 0.0001).
Publication bias
The funnel plot for the overall pooled analysis of the asso-
ciation between subtypes of EGFR mutations, and response 
(Fig. 6a) revealed no evidence of publication bias, with a 
symmetrical distribution of study results around the pooled 
measurement of effect. Moreover, the funnel plot for the 
Table 1  Characteristics of the 22 trials included in the meta-analysis
The quality of the randomized studies was assessed by using the Jadad Scale with 0–3 (low quality) and 4–5 (high quality). The quality of the 
nonrandomized studies was assessed by using the Newcastle-Ottawa Scale (NOS) with 0–5 (low quality) and 6–9 (high quality)
Ref. reference; C Caucasian; A Asian; pro prospective; retro retrospective; Treat line: 1 = only first-line EGFR TKI therapy; ≥2 = second-line 
therapy, third-line EGFR TKI therapy, ect.; mix = any one treat line EGFR TKI therapy
First author (year) Race Clinical stage Number Treat line Treatment Type of article Score
19 del 21 L858R ORR PFS OS
Sunaga et al. (2007) A III-IV 16 3 1 ✓ Pro 6
Yoshida et al. (2007) A IIIB-IV 8 13 Mix ✓ ✓ Pro 8
Sequist et al. (2008) C IIIB-IV 17 9 1 ✓ Pro 7
Yang et al. (2008) A IIIB-IV 20 23 1 ✓ ✓ Pro 6
Asahina et al. (2006) A IIIB-IV 13 3 Mix ✓ Pro 7
Fukuoka et al. (2011) A IIIB-IV 66 64 1 ✓ RCT 5
Maemondo et al. (2010) C IIIB-IV 58 42 1 ✓ ✓ RCT 4
Jackman et al. (2006) C IIIB-IV 22 10 1 ✓ ✓ Pro 7
Sutani et al. (2006) A III-IV 20 7 Mix ✓ Pro 8
Cappuzzo et al. (2007) C IIIB-IV 17 7 ≥2 ✓ ✓ Pro 6
Tamura et al. (2008) A III-IV 14 17 Mix ✓ Pro 7
Sugio et al. (2009) A IIIB-IV 7 10 1 ✓ Pro 6
Takano et al. (2007) A IIIB-IV 49 36 Mix ✓ ✓ Retro 6
Chou et al. (2005) A IIIB-IV 11 12 Mix ✓ Retro 5
Ichihara et al. (2007) A IIIB-IV 16 14 Mix ✓ Retro 7
Pallis et al. (2007) C IIIB-IV 6 3 ≥2 ✓ ✓ Retro 5
Wu (2010) A IIIB-IV 34 23 ≥2 ✓ ✓ ✓ Retro 5
Xu et al. (2009) A IIIB-IV 11 6 ≥2 ✓ ✓ ✓ Retro 7
Hirsch et al. (2007) C IIIB-IV 11 31 Mix ✓ ✓ ✓ Retro 7
马 (2013) A IIIB-IV 29 36 Mix ✓ Retro 4
Mitsudomi et al. (2010) A IIIB-IV 87 85 1 ✓ RCT 5
Rosell et al. (2009) C IIIB-IV 57 29 1 ✓ Pro 8
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overall pooled analysis of the association between types of 
EGFR mutations, and PFS (Fig. 6b) also revealed no evi-
dence of publication bias. The mean of the pooled effect 
was positive which indicated a potential publication bias in 
favor of more positive studies. However, the evaluation of 
publication bias using the funnel plot approach was some-
what limited by the small number of studies identified for 
inclusion in the pooled analyses.
Variance analysis
We, respectively, compared the PFS of 767 patients and the 
OS of 123 patients through variance analysis, using SPSS 
software.
As shown in Table 2, the PFS data are normally dis-
tributed (P > 0.05). The average PFS was 11.1 months in 
patients with the exon 19del mutation and 8.7 months in 
patients with the exon 21L858R mutation, this difference 
is statistically significant (P < 0.05). As the results of the 
rank and U test show, the overall survival data had a non-
normal distribution(P < 0.001), and the average overall sur-
vival in patients with the exon 19del mutation was 23.9 and 
13.0 months for patients with the exon 21L858R mutation, 
this difference is also statistically significant.
Discussion
The correlation of EGFR TKI efficacy and EGFR muta-
tions subtypes is the important factor in most of the large 
phase III clinical trials in NSCLC patients with EGFR 
sensitive mutations, but the results are difficult to com-
bine. According to analyses of the five US and Euro-
pean clinical trials that assessed first-line TKI treatment, 
Fig. 2  Forest plot of ORR among patients with EGFR 19del or 21L858R mutations. The squares and horizontal lines correspond to the study-
specific RR and 95 % CI. The area of the squares reflects the weight. The diamond represents the summary RR and the 95 % CI
1906 J Cancer Res Clin Oncol (2014) 140:1901–1909
1 3
Fig. 3  Forest plot of PFS among patients with EGFR 19del or 21L858R mutations with minimum SD. The squares and horizontal lines corre-
spond to the study-specific MD and 95 % CI. The area of the squares reflects the weight. The diamond represents the summary RR and 95 % CI
Fig. 4  Forest plot of PFS among patients with EGFR 19del or 21L858R mutations with maximum SD. The squares and horizontal lines corre-
spond to the study-specific MD and 95 % CI. The area of the squares reflects the weight. The diamond represents the summary RR and 95 % CI
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patients with the exon 19 deletion have a significantly 
longer progression-free and overall survival time than 
patients with L858R (30.8 vs. 14.8 months; P < 0.0001) 
(Morita et al. 2009). Studies on North American patients 
indicated that those with deletions of exon 19 in the EGFR 
have a better response rate, progression-free survival 
and overall survival after EGFR tyrosine kinase inhibi-
tor treatment than do those with the L858R mutation in 
exon 21 (Jackman et al. 2006; Riely et al. 2006). A Span-
ish study led by Rosell also indicated that patients with 
the 19del mutation had a better response than those with 
the L858R mutation (odds ratio, 3.08; 95 % CI 1.63–5.81; 
P = 0.001); however, there was no significant difference 
in the progression-free survival time with respect to muta-
tion type (Rosell et al. 2009). The results of the IPASS 
study showed that compared with the patients with the 
L858R mutation, the PFS of patients with the 19del muta-
tion was not statistically different (HR 0.55; 95 % CI 
0.35–0.87); however, the ORR was higher (84.8 %), but 
the difference was not statistically significant (OR 1.41; 
95 % CI 0.65–3.05) (Fukuoka et al. 2011). The same 
results were acquired from WJTOG3405 and EURTAC 
studies (Mitsudomi et al. 2010). Differences in the results 
of these studies may be related to the sample count. For 
this reason, we systematically evaluated the differences 
between the two common EGFR mutations and the effi-
cacy of EGFR TKIs.
Our analysis adds to our understanding of the impor-
tance of the influence of EGFR mutations on the efficacy of 
EGFR TKI. The results of this meta-analysis comparing the 
difference in efficacy of EGFR TKI in advanced NSCLC 
for the EGFR 19del and 21L858R mutations, confirms that 
the EGFR 19del mutations when treated with EGFR TKI 
show a better response rate and progression-delaying effect 
than the EGFR 21L858R mutations.
Fig. 5  Forest plot of OS among patients with EGFR 19del or 21L858R mutations. The squares and horizontal lines correspond to the study-
specific MD and 95 % CI. The area of the squares reflects the weight
Fig. 6  a Funnel plot of the relative ORR; b funnel plot of the relative PFS
Table 2  Variance analysis for the progression-free survival data, and 
rank and sum test—nonparametric (U test) for the overall survival 
data
19del 21L858R F (P value) P value P value 
(U test)
PFS (month) 11.1 8.7 3.673 (P > 0.05) 0.000
OS (month) 23.9 13.0 11.283 (P < 0.001) P < 0.05
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The results of this pooled analysis highlight the idea 
that the exon 19del mutation is a better indicator of strong 
efficacy in EGFR TKI treatment, which is an improve-
ment over findings in patients with lung cancer that have 
been reported previously. These results also contribute to 
evidence-based medicine in clinical work. Screening for 
EGFR mutations is warranted and should be performed 
before beginning therapy with EGFR TKIs, since the exon 
19del mutation implies a better outcome than the L858R 
mutation.
As our meta-analysis results have shown, the subgroup 
analysis showed that there was no statistically significant 
difference in PFS, the possible reason may be that the small 
sample size results in the lack of statistical significance. 
The number of subgroups in the included literature is too 
few, totaling only seven prospective studies and six retro-
spective studies. Moreover, only three cases in the literature 
were included in the pooled analysis of OS, so the sample 
number was low. Unfortunately, most of the prospective 
and retrospective studies failed to obtain the overall sur-
vival data, so the evaluation of the difference in OS needs 
further verification.
We estimated the standard deviation in order to evaluate 
the data of progression-free survival and overall survival 
for studies with a poor level of evidence-based medicine. 
Toward this end, we compared the difference in the mean 
for the two types of EGFR mutations and overall survival 
in patients using SPSS software. The results showed that 
progression-free survival and overall survival in patients 
with the exon 19del mutation were significantly longer 
than patients with the exon 21L858R mutation, which is in 
accordance with the results of the meta-analysis.
Comprehensive literature was included in this pooled 
analysis which contains both prospective and retrospective 
studies, and the number of objects was determined to be 
sufficiently large. The ORR, progression-free survival and 
overall survival were all selected to evaluate the difference 
in EGFR TKI efficacy between exon 19del and 21L858R 
mutations; our evaluation indicators are comprehensive 
thereby. However, our evaluation has the following limita-
tions; firstly, due to lack of research about the relationship 
between EGFR mutation type and the efficacy of EGFR 
TKI, all the data came from their subgroups, which could 
lead to the data being incomplete. Secondly, the instabil-
ity problems of the retrospective studies also influenced the 
quality of the system analysis.
Conclusion
The results of this system evaluation suggest that in III-
IV NSCLC patients with EGFR mutations, patients with 
the exon 19 deletion have a better response rate, and a 
significantly longer progression-free survival and overall 
survival than patients with the L858R mutation. Hence, the 
type of EGFR mutation has predictive value for EGFR TKI 
efficacy, and patients with the exon 19del mutation show 
a more prominent preponderance in efficacy for EGFR 
TKIs. The difference may be related to the different bio-
logical activities of EGFR mutations. The mechanism is 
not entirely clear, so further exploration is needed at the 
molecular level in the future.
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